Biliary tract cancer and PI3K pathway for nab-paclitaxel use

# 핵심 요약 - 1차 표준은 **GemCis + 면역항암제(듀발루맙/펨브롤리주맙)**로 자리 잡았고, **GemCis+nab-paclitaxel(GAP)**은 3상(SWOG S1815)에서 **OS 개선이 확인되지 않아 표준이 아님**. 단, **담낭암에서 PFS 향상 신호**가 탐색적으로 관찰. ([PubMed](https://pubmed.ncbi.nlm.nih.gov/38319896/?utm_source=chatgpt.com "Durvalumab plus Gemcitabine and Cisplatin in Advanced ...")) ([PubMed](https://pubmed.ncbi.nlm.nih.gov/39671534/ "SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers - PubMed")) - **PI3K/AKT/mTOR** 활성은 담도암의 **약물 저항성**과 관련되며, 다양한 암종에서 **PI3K 억제가 탁센 감수성 회복**에 기여한다는 근거가 축적. 담도암에서도 해당 경로 표적화의 논리적 근거가 강함(빈도는 아형·코호트에 따라 상이). ([Nature](https://www.nature.com/articles/s41419-020-02998-6?utm_source=chatgpt.com "PI3K/AKT pathway as a key link modulates the multidrug ..."), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC8569340/?utm_source=chatgpt.com "Chemoresistance in breast cancer: PI3K/Akt pathway ...")) ([PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9400790/?utm_source=chatgpt.com "Genomic alterations in cholangiocarcinoma: clinical ...")) - **nab-paclitaxel**은 **섬유화/기질 풍부(iCCA) 미세환경을 교란**하고 다제내성 모델에서 **약물 저항성을 완화**하는 전임상 데이터가 있다. 임상 2상에선 고무적 결과가 있었으나 3상에서 재현되지 못했다. ([PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019977/ "Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma - PMC"), [Frontiers](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.771418/full?utm_source=chatgpt.com "Paclitaxel Restores Sensitivity to Chemotherapy in ...")) ([JAMA Network](https://jamanetwork.com/journals/jamaoncology/fullarticle/2730639?utm_source=chatgpt.com "Gemcitabine, Cisplatin, and nab-Paclitaxel for the ..."), [PubMed](https://pubmed.ncbi.nlm.nih.gov/39671534/ "SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers - PubMed")) --- ## 1) 현재 치료 환경 요약 - **TOPAZ-1**: GemCis+듀발루맙이 OS·PFS 향상 → 1차 표준 확립. - **KEYNOTE-966**: GemCis+펨브롤리주맙도 OS 유의 개선. ([PubMed](https://pubmed.ncbi.nlm.nih.gov/38319896/?utm_source=chatgpt.com "Durvalumab plus Gemcitabine and Cisplatin in Advanced ..."), [The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2823%2900727-4/fulltext?utm_source=chatgpt.com "a randomised, double-blind, placebo-controlled, phase 3 trial")) ## 2) 왜 탁센/특히 nab-paclitaxel 인가? - 탁센은 미세소관 동역학을 억제하여 분열정지를 유도. **nab** 제형은 알부민 기반 운반으로 종양 기질 접근성이 개선될 수 있다(※ SPARC 연관성은 **예측표지자로 일관되게 검증되지 않음**). ([PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC25218/?utm_source=chatgpt.com "Taxol Suppresses Dynamics of Individual Microtubules in ..."), [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0168365913003337?utm_source=chatgpt.com "Review nab-Paclitaxel mechanisms of action and delivery"), [AACR Journals](https://aacrjournals.org/clincancerres/article/21/21/4811/175077/SPARC-Expression-Did-Not-Predict-Efficacy-of-nab?utm_source=chatgpt.com "SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel ...")) - iCCA 전임상 모델에서 **nab-paclitaxel이 암연관섬유아세포(CAF)와 섬유화 기질을 교란**하며 항종양 효과를 보였고, 다제내성 iCCA 모델에서 **(albumin-bound) paclitaxel이 종양 성장 지연·혈관재편·포도당섭취 감소**를 유도. ([PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019977/ "Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma - PMC"), [Frontiers](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.771418/full?utm_source=chatgpt.com "Paclitaxel Restores Sensitivity to Chemotherapy in ...")) ## 3) 임상 근거: GAP 요법 - **단일군 2상(JAMA Oncol 2019)**: GemCis+nab-paclitaxel에서 역사적 대조 대비 PFS·OS 연장 보고(중앙 OS 약 19개월로 기술). 이를 바탕으로 3상 진행. ([JAMA Network](https://jamanetwork.com/journals/jamaoncology/fullarticle/2730639?utm_source=chatgpt.com "Gemcitabine, Cisplatin, and nab-Paclitaxel for the ...")) - **3상 SWOG S1815(JCO 2025; 2024.12 전자출판)**: GAP vs GemCis 무작위 비교에서 - **중앙 OS** 14.0 vs 13.6개월(HR 0.91; P=0.41)로 **차이 없음** - **중앙 PFS** 7.5 vs 6.3개월(HR 0.89; P=0.32) - **담낭암(GBC)**에서 **PFS 상호작용 P=0.01**로 **향상 신호**(OS은 아님) - **독성은 GAP가 더 많음** → **표준요법 불인정**. ([PubMed](https://pubmed.ncbi.nlm.nih.gov/39671534/ "SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers - PubMed")) ## 4) PI3K/AKT/mTOR 경로와 탁센의 접점 - PI3K 경로 활성(PIK3CA 변이, PTEN 소실, p-AKT)은 세포생존·항아폽토시스 신호를 통해 **항암제 내성**에 기여하며, **경로 억제가 탁센 감수성 회복**과 연관된 전임상·임상초기 근거가 다수 보고(여러 암종). ([Nature](https://www.nature.com/articles/s41419-020-02998-6?utm_source=chatgpt.com "PI3K/AKT pathway as a key link modulates the multidrug ..."), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC8569340/?utm_source=chatgpt.com "Chemoresistance in breast cancer: PI3K/Akt pathway ..."), [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S1368764602001206?utm_source=chatgpt.com "Activation of the PI3K/Akt pathway and chemotherapeutic ...")) - 담도암에서 PI3K 표적화의 타당성: 체계적 리뷰 및 최신 개관 논문에서 경로의 **생물학적 중요성 및 치료 타깃성**을 강조. ([PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9400790/?utm_source=chatgpt.com "Genomic alterations in cholangiocarcinoma: clinical ...")) ### 빈도(예시) - **GBC**: PIK3CA 변이 빈도 보고가 코호트별로 **~6–33%**까지 다양. ([BioMed Central](https://jeccr.biomedcentral.com/articles/10.1186/s13046-016-0370-7?utm_source=chatgpt.com "The E545K mutation of PIK3CA promotes gallbladder ..."), [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0344033822000498?utm_source=chatgpt.com "Genomic profiling of gallbladder carcinoma: Targetable ...")) - **iCCA/eCCA**: PIK3CA/PI3K축 변이는 **소수이지만 존재**, PTEN 변화 및 mTOR 축 활성 사례 보고. ([PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9400790/?utm_source=chatgpt.com "Genomic alterations in cholangiocarcinoma: clinical ...")) ## 5) 임상적 함의(실전 요약) 1. **1차 치료** - **GemCis+듀발루맙/펨브롤리주맙**이 글로벌 표준. **GAP 추가는 3상 음성**이므로 **일반적 권고 대상 아님**. ([PubMed](https://pubmed.ncbi.nlm.nih.gov/38319896/?utm_source=chatgpt.com "Durvalumab plus Gemcitabine and Cisplatin in Advanced ...")) 2. **하위군 가설** - **담낭암**에서 **PFS 신호**가 있어, 임상시험 맥락에서 **바이오마커·아형 특정 전략**을 재검증할 가치. ([PubMed](https://pubmed.ncbi.nlm.nih.gov/39671534/ "SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers - PubMed")) 3. **전임상·전략적 조합** - **PI3K/AKT/mTOR 억제제 + nab-paclitaxel**은 **기전적 시너지가 가설적으로 강함**(내성 역전·세포주기/기질 영향). 담도암에서 **전향적 임상시험**이 필요. ([Nature](https://www.nature.com/articles/s41419-020-02998-6?utm_source=chatgpt.com "PI3K/AKT pathway as a key link modulates the multidrug ..."), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019977/ "Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma - PMC"), [Frontiers](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.771418/full?utm_source=chatgpt.com "Paclitaxel Restores Sensitivity to Chemotherapy in ...")) 4. **바이오마커 실무 체크리스트** - **NGS**: _PIK3CA, PTEN, AKT1/2, mTOR, TSC1/2_ 등 - **IHC/포스포-프로테옴**: p-AKT(S473), p-S6, PTEN - **ctDNA**(혈장/담즙): 조직 확보 어려운 담도암에서 보조적 활용 - **기질 지표**: CAF/섬유화 서명, TME 관련 전사체 서명(연구용) ([Exploration Publishing](https://www.explorationpub.com/Journals/etat/Article/1002328?utm_source=chatgpt.com "Biliary tract cancers: advances in diagnostic and ...")) ## 6) 연구 제안(바이오마커 기반 2상 스케치) - **대상**: 전이성 담낭암 또는 기질풍부 iCCA, **PI3K 경로 활성**(PIK3CA 변이/ PTEN 소실/ p-AKT 양성) 선정 - **치료**: GemCis+면역항암제 표준 이후 **nab-paclitaxel ± PI3K/AKT/mTOR 억제제**(용량-탐색 후 확장) - **주요평가**: ORR/PFS; **공동 탐색표지자**(ctDNA 변이대역폭, p-AKT, CAF 서명 변화) - **근거**: 3상 음성 결과를 고려하되(독성 고려), **PI3K 활성·아형 특이성**을 전향적으로 가려내 **정밀집단에서의 효과**를 검증. ([PubMed](https://pubmed.ncbi.nlm.nih.gov/39671534/ "SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers - PubMed"), [Nature](https://www.nature.com/articles/s41419-020-02998-6?utm_source=chatgpt.com "PI3K/AKT pathway as a key link modulates the multidrug ...")) --- ## 참고문헌(선택) - SWOG S1815 3상: GAP vs GemCis, **OS 개선 불인정**, GBC PFS 신호·독성 증가. ([PubMed](https://pubmed.ncbi.nlm.nih.gov/39671534/ "SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers - PubMed")) - GemCis+nab-paclitaxel 2상 단일군: 역사적 대조 대비 생존 연장 보고. ([JAMA Network](https://jamanetwork.com/journals/jamaoncology/fullarticle/2730639?utm_source=chatgpt.com "Gemcitabine, Cisplatin, and nab-Paclitaxel for the ...")) - iCCA 전임상: **nab-paclitaxel의 기질 교란/항종양 효과**. ([PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019977/ "Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma - PMC")) - iCCA 다제내성 모델: **albumin-bound paclitaxel이 저항성 완화**. ([Frontiers](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.771418/full?utm_source=chatgpt.com "Paclitaxel Restores Sensitivity to Chemotherapy in ...")) - 표준 1차 면역병용: **TOPAZ-1**, **KEYNOTE-966**. ([PubMed](https://pubmed.ncbi.nlm.nih.gov/38319896/?utm_source=chatgpt.com "Durvalumab plus Gemcitabine and Cisplatin in Advanced ...")) - 담도암 유전체/PI3K 경로 개관. ([PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9400790/?utm_source=chatgpt.com "Genomic alterations in cholangiocarcinoma: clinical ...")) - GBC에서 PIK3CA 빈도(코호트 가변, 6–33%). ([BioMed Central](https://jeccr.biomedcentral.com/articles/10.1186/s13046-016-0370-7?utm_source=chatgpt.com "The E545K mutation of PIK3CA promotes gallbladder ..."), [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0344033822000498?utm_source=chatgpt.com "Genomic profiling of gallbladder carcinoma: Targetable ...")) - PI3K 활성과 약제내성/탁센 감수성 연관(다암종 근거). ([Nature](https://www.nature.com/articles/s41419-020-02998-6?utm_source=chatgpt.com "PI3K/AKT pathway as a key link modulates the multidrug ..."), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC8569340/?utm_source=chatgpt.com "Chemoresistance in breast cancer: PI3K/Akt pathway ...")) --- ### 실무 한 줄 메모 - **현재**: GemCis+IO → **표준**. - **GAP**: 루틴 사용 X(3상 음성·독성↑), 단 **담낭암·PI3K 활성·기질풍부 아형** 등 **정밀 하위군 임상시험**은 가치 있음. ([PubMed](https://pubmed.ncbi.nlm.nih.gov/39671534/ "SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers - PubMed"))